Aditya Juloori to Combined Modality Therapy
This is a "connection" page, showing publications Aditya Juloori has written about Combined Modality Therapy.
Connection Strength
0.630
-
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
Score: 0.178
-
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
Score: 0.178
-
Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
Score: 0.156
-
Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy. J Thorac Oncol. 2014 Apr; 9(4):534-40.
Score: 0.087
-
Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. J Neurosurg. 2020 02 01; 132(2):503-511.
Score: 0.030